Immunosuppression may be present within condyloma acuminata

Journal of the American Academy of Dermatology

Volumn 59, Issue 6, 2008, Pages 967-974

  Le Poole, Caroline ^a   Denman, Cecele J ^a   Arbiser, Jack L ^b  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBONATE DEHYDRATASE IX; CD40 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR ALPHA; TRANSCRIPTION FACTOR FOXP3;

ANTIGEN DETECTION; ARTICLE; CELL COUNT; CELL INFILTRATION; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONDYLOMA ACUMINATUM; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; KERATINOCYTE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE;

ADULT; ANTIGENS, CD40; ANTIGENS, NEOPLASM; CARBONIC ANHYDRASES; CHEMOKINE CCL1; CONDYLOMATA ACUMINATA; FEMALE; HUMANS; IMMUNE TOLERANCE; IMMUNOHISTOCHEMISTRY; INFANT, NEWBORN; MALE; POLYMERASE CHAIN REACTION; T-LYMPHOCYTES, REGULATORY;

EID: 55949097978     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2008.08.011     Document Type: Article

References (34)

1. Arany I., Rady P., and Tyring S.K. Alterations in cytokine/antioncogene expression in skin lesions caused by "low-risk" types of human papillomaviruses. Viral Immunol 6 (1993) 255-265
2. Baker C.C., Phelps W.C., Lindgren V., Braun M.J., Gonda M.A., and Howley P.M. Structural and transcriptional analysis of human papillomavirus type 16 sequences in cervical carcinoma cell lines. J Virol 61 (1987) 962-971
3. Barbosa M.S., Vass W.C., Lowy D.R., and Schiller J.T. In vitro biological activities of the E6 and E7 genes vary among human papillomaviruses of different oncogenic potential. J Virol 65 (1991) 292-298
4. de Oliveira W.R., Rady P.L., Grady J., Hughes T.K., Neto C.F., Rivitti E.A., et al. Association of p53 arginine polymorphism with skin cancer. Int J Dermatol 43 (2004) 489-493
5. Frazer I.H., Lowy D.R., and Schiller J.T. Prevention of cancer through immunization: prospects and challenges for the 21st century. Eur J Immunol 37 Suppl (2007) S148-S155
6. Garcia-Pineres A., Hildesheim A., Dodd L., Kemp T.J., Williams M., Harro C., et al. Cytokine and chemokine profiles following vaccination with human papillomavirus type 16 L1 virus-like particles. Clin Vaccine Immunol 14 (2007) 984-989
7. Smith J.F., Brownlow M., Brown M., Kowalski R., Esser M.T., Ruiz W., et al. Antibodies from women immunized with Gardasil cross-neutralize HPV 45 pseudovirions. Hum Vaccin 3 (2007) 109-115
8. Van der Loos C.M., Das P.K., Van den Ooord J.J., and Houthoff H.J. Multiple immunoenzyme staining techniques. Use of fluoresceinated, biotinylated and unlabeled monoclonal antibodies. J Immunol Meth 117 (1989) 45-52
9. Cooper K.D., Androphy E.J., Lowy D., and Katz S.I. Antigen presentation and T-cell activation in epidermodysplasia verruciformis. J Invest Dermatol 94 (1990) 769-776
10. De Bruijn M.L., Greenstone H.L., Vermeulen H., Melief C.J., Lowy D.R., Schiller J.T., et al. L1-specific protection from tumor challenge elicited by HPV16 virus-like particles. Virology 250 (1998) 371-376
11. Arany I., Grattendick K.G., and Tyring S.K. Interleukin-10 induces transcription of the early promoter of human papillomavirus type 16 (HPV16) through the 5'-segment of the upstream regulatory region (URR). Antiviral Res 55 (2002) 331-339
12. Pinto L.A., Viscidi R., Harro C.D., Kemp T.J., Garcia-Pineres A.J., Trivett M., et al. Cellular immune responses to HPV-18, -31, and -53 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles. Virology 353 (2006) 451-462
13. Schiller J.T., and Lowy D.R. Papillomavirus-like particle based vaccines: cervical cancer and beyond. Expert Opin Biol Ther 1 (2001) 571-581
14. Beutner K.R., and Tyring S. Human papillomavirus and human disease. Am J Med 102 (1997) 9-15
15. Tyring S.K. Human papillomavirus infections: epidemiology, pathogenesis, and host immune response. J Am Acad Dermatol 43 Suppl (2000) S18-S26
16. Zheng Z.M., and Baker C.C. Papillomavirus genome structure, expression, and post-transcriptional regulation. Front Biosci 11 (2006) 2286-2302
17. Gaspari A.A., Zalka A.D., Payne D., Menegus M., Bunce L.A., Abboud C.N., et al. Successful treatment of a generalized human papillomavirus infection with granulocyte-macrophage colony-stimulating factor and interferon gamma immunotherapy in a patient with a primary immunodeficiency and cyclic neutropenia. Arch Dermatol 133 (1997) 491-496
18. Sanclemente G., Herrera S., Tyring S.K., Rady P.L., Zuleta J.J., Correa L.A., et al. Human papillomavirus (HPV) viral load and HPV type in the clinical outcome of HIV-positive patients treated with imiquimod for anogenital warts and anal intraepithelial neoplasia. J Eur Acad Dermatol Venereol 21 (2007) 1054-1060
19. Schell B.J., Rosen T., Rady P., Arany I., Tschen J.A., Mack M.F., et al. Verrucous carcinoma of the foot associated with human papillomavirus type 16. J Am Acad Dermatol 45 (2001) 49-55
20. Kreuter A., Potthoff A., Brockmeyer N.H., Gambichler T., Stucker M., Altmeyer P., et al. Imiquimod leads to a decrease of human papillomavirus DNA and to a sustained clearance of anal intraepithelial neoplasia in HIV-infected men. J Invest Dermatol 128 (2008) 2078-2083
21. Yang C.H., Murti A., Pfeffer S.R., Kim J.G., Donner D.B., and Pfeffer L.M. Interferon alpha/beta promotes cell survival by activating nuclear factor kappa B through phosphatidylinositol 3-kinase and Akt. J Biol Chem 276 (2001) 13756-13761
22. Muller-Hermelink N., Braumuller H., Pichler B., Wieder T., Mailhammer R., Schaak K., et al. TNFR1 signaling and IFN-gamma signaling determine whether T cells induce tumor dormancy or promote multistage carcinogenesis. Cancer Cell 13 (2008) 507-518
23. +. J Clin Invest 116 (2006) 2434-2441
24. Vambutas A., DeVoti J., Pinn W., Steinberg B.M., and Bonagura V.R. Interaction of human papillomavirus type 11 E7 protein with TAP-1 results in the reduction of ATP-dependent peptide transport. Clin Immunol 101 (2001) 94-99
25. Tao J., Zhang X.P., Chen X.P., Li Y., Liu Y.Q., Tian J., et al. Local expression of TAP-1 and MHC-I molecules and their relationship in condyloma acuminatum. Clin Exp Dermatol 32 (2007) 550-555
26. Casp C.B., She J.X., and McCormack W.T. Genes of the LMP/TAP cluster are associated with the human autoimmune disease vitiligo. Genes Immun 4 (2003) 492-499
27. Arbiser J.L., Bingaman A., Durham M., Cowan S., Cohen C., Zarnegar E., et al. SVR angiosarcomas can be rejected by CD4 costimulation dependent and CD8 costimulation independent pathways. Mol Med 8 (2002) 551-558
28. +)-derived T regulatory cell lines express FoxP3 protein and manifest potent suppressor function. Blood 105 (2005) 750-758
29. + regulatory T cell function. Eur J Immunol 34 (2004) 2996-3005
30. Rubtsov Y.P., Rasmussen J.P., Chi E.Y., Fontenot J., Castelli L., Ye X., et al. Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces. Immunity 28 (2008) 546-558
31. Bui M.H., Seligson D., Han K.R., Pantuck A.J., Dorey F.J., Huang Y., et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res 9 (2003) 802-811
32. Gudbjartsson D.F., Sulem P., Stacey S.N., Goldstein A.M., Rafnar T., Sigurgeirsson B., et al. ASIP and TYR pigmentation variants associate with cutaneous melanoma and basal cell carcinoma. Nat Genet 40 (2008) 886-891
33. + regulatory T cells in the inhibition of antitumor CD8 T-cell responses. Cancer Res 65 (2005) 8479-8486
34. Cerimele F., Battle T., Lynch R., Frank D.A., Murad E., Cohen C., et al. Reactive oxygen signaling and MAPK activation distinguish Epstein-Barr Virus (EBV)-positive versus EBV-negative Burkitt's lymphoma. Proc Natl Acad Sci USA 102 (2005) 175-179